Roswell Park Comprehensive Cancer Center’s Igor Puzanov, MD, MSCI, FACP, Andrew Hyland, PhD, and Maciej Goniewicz, PhD, PharmD, have all recently been recognized as global scientific pioneers on Clarivate Plc’s Highly Cited Researchers list for 2020. The list recognizes researchers who have demonstrated “significant influence” through papers that have been highly cited, or referred to in publications from other researchers, over the past 10 years. Drs. Puzanov, Hyland, and Goniewicz have all authored publications that rank in the top 1% for their given field.
Recent projects from these scientists are outlined below:
Dr. Puzanov, Senior Vice President of Clinical Investigation, Director of the Center for Early Phase Clinical Trials, Chief of Melanoma, was lead author on a 10-year retrospective look at three randomized clinical trials in advanced melanoma.1 Published in JAMA Oncology in July, the study supported the use of therapeuic pembrolizumab.
Dr. Hyland, Chair of Health Behavior, is scientific lead for the ongoing Population Assessment of Tobacco and Health (PATH) Study. Published in Tobacco Control in late May,2 the study revealed that e-cigarette usage is not nearly as persistent as cigarette smoking.
Funded by a 5-year, $19.05 million National Cancer Institute grant, Dr. Goniewicz and the WNY Center for Research on Flavored Tobacco Products are examining combustible and electronic tobacco products. This year, Dr. Goniewicz contributed to a research letter published in TheNew England Journal of Medicine regarding the effects of a cutting agent, vitamin E acetate, used in illicit cannabis vaping products.3
References
1. Puzanov I, et al: Association of BRAF V600E/K mutation status and prior BRAF/MEK inhibition with pembrolizumab outcomes in advanced melanoma. JAMA Oncol 6:1256-1264, 2020.
2. Hyland A, et al: Overview of tobacco use transitions for population health. Tobacco Control 29:s134-s138, 2020.
